Our Science – Feldman Website
Steven A. Feldman, Ph.D.
The NCI Surgery Branch Vector Production Facility is charged with producing clinical grade retroviral vectors in support of our clinical trials. The majority of patients with advanced metastatic cancer now enrolled in clinical trials in the Surgery Branch have failed conventional and most experimental treatments including chemotherapy, high-dose IL-2 treatment, vaccination with tumor antigen peptides and recombinant viruses that encode tumor antigens, as well as adoptive transfer of autologous tumor reactive T cells. Overall, despite all of these intensive treatment options, durable responses have only been observed in a limited number of patients, demonstrating the urgent need for the development of new and more effective cancer treatments. The clinical reagents produced in the Surgery Branch Vector Production Facility will be used for expressing anti-cancer genes within immune cells for use in cancer immunotherapy trials. These trials will allow the evaluation of the effectiveness of genetically engineered human T lymphocytes and other cells of the immune system to express anti-cancer genes and cause tumor regression in patients enrolled in our cancer immunotherapy trials.
This page was last updated on 2/26/2013.